GATA6 and esophageal adenocarcinoma: Some studies with relatively small cohorts of patients (n = 73, respectively, n = 58) reported poor prognosis in patients with GATA6 amplifications (Lin et al. 2012; Toxopeus et al. 2019) while another analysis including two separated cohorts (first cohort: 130 tissue samples of normal squamous epithelium, metaplasia, dysplasia, and esophageal adenocarcinoma; second cohort: 92 esophageal adenocarcinoma) demonstrated no association between GATA6 and overall or disease-free survival in this entity (Pavlov et al. 2015).